Clinical Insights on R/R Follicular Lymphoma: ASH 2024 Highlights - Episode 10

Navigating the Evolving Treatment Landscape in R/R FL: When to Consider BTK and EZH2 Inhibitors

Panelists discuss how they collaborate with community sites for chimeric antigen receptor (CAR) T and bispecifics administration, accessibility, and monitoring, and explore the factors influencing the use of tazemetostat or zanubrutinib + obinutuzumab, including patient selection, accessibility, and sequencing in relation to CAR T or bispecific therapies.

EP. 1: Treatment Strategies in 2L R/R FL: When to Treat vs Observe in Relapsed Disease
EP. 2: Clinical Perspectives Selecting 2L Treatment Options in R/R FL: Chemoimmunotherapy vs Lenalidomide Combinations in Relapsed Disease
EP. 3: ASH 2024 Updates: inMIND study With Tafasitamab Combined With Lenalidomide and Rituximab in R/R FL
EP. 4: Expert Insights: How Tafasitamab + R2 May Impact Clinical Practice in R/R FL
EP. 5: Exploring Tafasitamab in 2L Treatment: Challenges, Impact on Decision-Making, and Key Insights From inMIND Study
EP. 6: ASH 2024 Updates: EPCORE NHL-2 Trial With Fixed-Duration Epcoritamab + R2
EP. 7: Differentiating Treatment Options: Epcoritamab + R2 vs Tafasitamab-Lenalidomide-Rituximab in R/R FL
EP. 8: Choosing Bispecifics in 3L Treatment Setting R/R FL
EP. 9: ASH 2024 CAR T and Bispecifics Updates: Key Insights and Practical Considerations in 3L R/R FL Treatment
Now Viewing
EP. 10: Navigating the Evolving Treatment Landscape in R/R FL: When to Consider BTK and EZH2 Inhibitors
EP. 11: Expert Perspectives: Sequencing Tafasitamab + R2 With Currently Available Options in 3L Setting
EP. 12: Reflecting on 2024: Key Achievements and Looking Ahead to 2025 in R/R FL Treatment

Video content above is prompted by the following:

  • How do you partner or collaborate with community sites regarding CAR T and bispecifics administration, accessibility, and monitoring?
  • Which patients do you consider tazemetostat or zanubrutinib + obinutuzumab for, and how does accessibility of these agents factor? How are you sequencing these agents in relationship to CAR T or the bispecifics?